Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 2 of 3 for:    prevail watchman

Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology (CAP2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01760291
Recruitment Status : Completed
First Posted : January 4, 2013
Results First Posted : November 24, 2021
Last Update Posted : March 29, 2022
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Device: WATCHMAN LAA Closure Technology Not Applicable

Detailed Description:
This Continued Access Protocol is a prospective, non-randomized, multicenter study to allow continued access to the WATCHMAN LAA Closure Technology during the data analysis, reporting and review of the PREVAIL pivotal study Pre-Market Application by FDA.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 576 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology
Study Start Date : September 2012
Actual Primary Completion Date : April 2019
Actual Study Completion Date : April 2019

Arm Intervention/treatment
Experimental: WATCHMAN
WATCHMAN LAA Closure Technology
Device: WATCHMAN LAA Closure Technology

Primary Outcome Measures :
  1. Number of Participants With Ischemic Stroke [ Time Frame: 5 Year Follow Up ]
    Primary Endpoint Events by Type for Enrolled Subjects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: A subject may be enrolled in the study if all of the following inclusion criteria are met:

  1. The subject is 18 years of age or older
  2. The subject has documented paroxysmal, persistent, or permanent non- valvular atrial fibrillation (i.e., the subject has not been diagnosed with rheumatic mitral valvular heart disease)
  3. The subject is eligible for long-term warfarin therapy
  4. The subject has a calculated CHADS2 score of 2 or greater; Subjects with a CHADS2 score of 1 may be included if any of the following apply (according to the ACC/AHA/ESC 2006 Guidelines for the Management of

    Subjects with Atrial Fibrillation subjects requiring warfarin therapy):

    • The subject is a female age 75 or older
    • The subject has a baseline Left Ventricular Ejection Fraction (LVEF) > 30% and < 35%
    • The subject is age 65-74 and has diabetes or coronary artery disease
    • The subject is age 65 or greater and has documented congestive heart failure
  5. The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial
  6. The subject is able and willing to return for required follow-up visits and examinations

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the following criteria:

  1. The subject requires long-term warfarin therapy (i.e., even if the device is implanted, the subjects would not be eligible to discontinue warfarin due to other medical conditions requiring chronic warfarin therapy). Additionally, a subject with any of the following is excluded:

    • Thrombosis occurring at a young age (<40 years old)
    • Idiopathic or recurrent venous thromboembolism
    • Thrombosis at an unusual site (i.e., cerebral veins, hepatic veins,renal veins, inferior vena cava, mesenteric veins)
    • Family history of venous thromboembolism or of inherited prothrombotic disorder
    • Recurrence or extension of thrombosis while adequately anticoagulated
  2. The subject is contraindicated for warfarin therapy or cannot tolerate long-term warfarin therapy
  3. The subject is contraindicated or allergic to aspirin
  4. The subject is indicated for antiplatelet therapy other than aspirin (for example, a subject indicated for clopidogrel, prasugrel, ticlopidine or ticagrelor due to DES is excluded from enrollment during the dosing regimen). A subject completing a course of antiplatelet therapy may be enrolled after a 7 day washout period
  5. The subject had any interventional or surgical procedure within 30 days prior to enrollment or is planning to have an interventional or surgical procedure in the time between the WATCHMAN device implant and 45-day TEE (e.g., cardioversion, ablation, cataract surgery, dental surgery)
  6. The subject had a prior stroke or TIA within the 90 days prior to enrollment
  7. The subject has had an MI within 90 days prior to enrollment
  8. The subject has a history of atrial septal repair or has an ASD/PFO device
  9. The subject has an implanted mechanical valve prosthesis
  10. The subject suffers from New York Heart Association Class IV Congestive Heart Failure at the time of enrollment
  11. The subject has symptomatic carotid disease (defined as >50% stenosis with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is < 50% stenosis
  12. The subject's AF is defined by a single occurrence of AF
  13. The subject had a transient case of AF (i.e., secondary to CABG, interventional procedure, etc.)
  14. The subject's left atrial appendage is obliterated
  15. The subject has undergone heart transplantation
  16. The subject is currently treated with antibiotics for an active infection
  17. The subject has a resting heart rate > 110 bpm
  18. The subject has thrombocytopenia (defined as < 70,000 platelets/mm3) or anemia with hemoglobin concentration of < 10 g/dl (i.e., anemia as determined by the investigator which would require transfusion)
  19. The subject is actively enrolled in a concurrent clinical study of an investigational drug or investigational device (study specifics may be reviewed with the sponsor prior to enrollment to confirm a concurrent study will not interfere with the outcomes of this study)
  20. The subject participated in any of the following studies: PROTECT AF, CAP Registry, or PREVAIL. If the subject received a subject ID number for a prior WATCHMAN study, the subject may not be enrolled. PROTECT AF control subjects may be considered for participation if they have completed 5 year follow up
  21. The subject is pregnant or pregnancy is planned during the course of the investigation
  22. The subject has a life expectancy of less than two years
  23. The subject is unable to complete follow-up visits for the duration of the study

Echo Exclusion Criteria

A subject is excluded from the study if any of the following echocardiographic exclusion criteria (as assessed via TTE and TEE) are met:

  1. The subject has LVEF < 30%
  2. The subject has intracardiac thrombus or dense spontaneous echo contrast as visualized by TEE and determined by the echocardiographer within 2 days prior to implant
  3. The subject has an existing pericardial effusion > 2mm
  4. The subject has a high risk patent foramen ovale (PFO) with an atrial septal aneurysm excursion > 15mm or length > 15mm
  5. The subject has a high risk PFO with a large shunt defined as early, within 3 beats or substantial passage of bubbles
  6. The subject has significant mitral valve stenosis (i.e., MV <1.5 cm2)
  7. The subject has complex atheroma with mobile plaque of the descending aorta or aortic arch
  8. The subject has a cardiac tumor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01760291

Layout table for location information
United States, Arizona
Arizona Heart Rhythm Research Center
Phoenix, Arizona, United States, 85006
United States, Kentucky
Central Baptist Hospital
Lexington, Kentucky, United States, 40503
United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10029
Sponsors and Collaborators
Boston Scientific Corporation
Layout table for investigator information
Principal Investigator: Saibal Kar, M.D. Cedars-Sinai Medical Center
Principal Investigator: Shephal Doshi, M.D. Pacific Heart
  Study Documents (Full-Text)

Documents provided by Boston Scientific Corporation:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boston Scientific Corporation Identifier: NCT01760291    
Other Study ID Numbers: S2278
First Posted: January 4, 2013    Key Record Dates
Results First Posted: November 24, 2021
Last Update Posted: March 29, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes